TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18640991

Group type: EXPERIMENTAL
Intervention: ET-1 infusion (1.0-2.5 ng kg(‐1) min(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ET-1 infusion
Number of subjects: 9
Study: 16801464

Group type: EXPERIMENTAL
Intervention: Thrombectomy pretreatment
Number of subjects: 215

Group type: COMPARATOR
Intervention: Standard PCI (Control)
Number of subjects: 215
Study: 14507836

Group type: EXPERIMENTAL
Intervention: Day 2 transfer
Number of subjects: 193

Group type: COMPARATOR
Intervention: Day 5 transfer
Number of subjects: 193
Study: 11028255

Group type: EXPERIMENTAL
Intervention: Autogenic-feedback training exercise (AFTE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Promethazine (25 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Promethazine (50 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 33
Study: 8899773

Group type: EXPERIMENTAL
Intervention: Free bone graft (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Osteoperiosteal trapdoor (group B)
Number of subjects: 20
Study: 1672059

Group type: EXPERIMENTAL
Intervention: isostable group (isoflurane maintained at 1.25%)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: isostop group (isoflurane discontinued before neostigmine administration)
Number of subjects: 36

Group type: COMPARATOR
Intervention: control group (fentanyl/N2O only)
Number of subjects: 36
Study: 6839001

Group type: EXPERIMENTAL
Intervention: enteric‐coated ASA (ecASA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: compressed ASA tablets (cASA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: sodium salicylate (578 mg)
Number of subjects: 12
Study: 30639991

Group type: EXPERIMENTAL
Intervention: Group CBTp plus treatment as usual (TAU)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Psychoeducation group (PsyEdI) plus TAU
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group CBTp
Number of subjects: 48
Study: 30480729

Group type: EXPERIMENTAL
Intervention: Lanadelumab 150 mg every 4 weeks (n=28)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 4 weeks (n=29)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 2 weeks (n=27)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 125
Study: 25665812

Group type: EXPERIMENTAL
Intervention: Supplemental insulin at bedtime for blood glucose (BG) >7.8 mmol/L
Number of subjects: 206

Group type: COMPARATOR
Intervention: No supplemental insulin except for BG >19.4 mmol/L
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Supplemental insulin at bedtime
Number of subjects: 206

Group type: COMPARATOR
Intervention: No supplemental insulin
Number of subjects: 206
Study: 24814472

Group type: EXPERIMENTAL
Intervention: Immediate treatment (mindfulness-based therapy)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 117
Study: 19181486

Group type: EXPERIMENTAL
Intervention: prulifloxacin associated with ProstaMEV and FlogMEV
Number of subjects: 143

Group type: COMPARATOR
Intervention: antibiotic therapy alone (prulifloxacin 600 mg daily for 14 days)
Number of subjects: 143
Study: 15631092

Group type: EXPERIMENTAL
Intervention: Xiao Gu San
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study: 12133539

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a dosage of 1.0 - 1.5 g/d
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) pulse therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 46
Study: 9650871

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan, 2.0% copolymer, 0.243% sodium fluoride)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control dentifrice (identical to test but without triclosan/copolymer)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 641
Study: 8703313

Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom (B-V)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2138973

Group type: EXPERIMENTAL
Intervention: EE/GSD
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EE/DG
Number of subjects: 11
Study: 7372823

Group type: EXPERIMENTAL
Intervention: Alpha biofeedback training
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo biofeedback
Number of subjects: 66

Group type: COMPARATOR
Intervention: No-treatment controls
Number of subjects: 66
Study: 31840808

Group type: EXPERIMENTAL
Intervention: Highest quintiles of the Alternative Healthy Eating Index (aHEI)
Number of subjects: 9861

Group type: EXPERIMENTAL
Intervention: Highest quintiles of the Dietary Approaches to Stop Hypertension (DASH)
Number of subjects: 9861

Group type: EXPERIMENTAL
Intervention: Highest quintiles of the Mediterranean Diet Score (MDS)
Number of subjects: 9861

Group type: EXPERIMENTAL
Intervention: Diet quality scores (measured by aHEI, DASH, MDS)
Number of subjects: 9861
Study: 30623248

Group type: EXPERIMENTAL
Intervention: Generic formulation with amorphous form of BCS 2 class drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference drug product with crystalline form
Number of subjects: 0
Study: 27688475

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neoadjuvant endocrine therapy (NET)
Number of subjects: 26
Study: 25039290

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Community children (never institutionalized)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study: 25326691

Group type: COMPARATOR
Intervention: Placebo dopaminergic manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dopaminergic medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22978189

Group type: EXPERIMENTAL
Intervention: Motor Skill Assessment Program (MSAP) training
Number of subjects: 36
Study: 20455982

Group type: EXPERIMENTAL
Intervention: T-VAC (duty-cycled, bipolar-unipolar RF generator with hexapolar tip)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ConvRF (conventional RF ablation with 8-mm tip catheter)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: T-VAC
Number of subjects: 60

Group type: COMPARATOR
Intervention: ConvRF
Number of subjects: 60
Study: 17547760

Group type: EXPERIMENTAL
Intervention: Active strategy (training module with administration of the guideline)
Number of subjects: 6395

Group type: EXPERIMENTAL
Intervention: Passive dissemination (administration of the guideline only)
Number of subjects: 6395

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 6395
Study: 15774254

Group type: EXPERIMENTAL
Intervention: Potassium paraaminobenzoate (4 x 3g/day for 12 months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 12356704

Group type: COMPARATOR
Intervention: Multidisciplinary training sessions on the active management of back pain delivered by a generic primary care educator or a clinical back pain expert.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training delivered by a clinical back pain expert.
Number of subjects: 0
Study: 9861607

Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation (200 micrograms daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study: 7836052

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cefonicid
Number of subjects: 102
Study: 2192073

Group type: EXPERIMENTAL
Intervention: Pulse-dosed antibiotics administered in a single daily dose
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 212170

Group type: EXPERIMENTAL
Intervention: Radiotherapy with CCNU and hydroxyurea
Number of subjects: 346

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 346
Study: 31335979

Group type: EXPERIMENTAL
Intervention: Insulin plus liraglutide 0.6 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 70
Study: 28884856

Group type: EXPERIMENTAL
Intervention: Adalimumab trough level at week 26
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab trough level of 5.0 μg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAA development at week 26
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6TGN level >222.5 p mol/8 ×108 RBCs
Number of subjects: 0
Study: 25326519

Group type: EXPERIMENTAL
Intervention: CAG with autologous blood (Group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: CAG with fibrin glue (Group II)
Number of subjects: 200
Study: 23109001

Group type: EXPERIMENTAL
Intervention: Machined pure titanium (MPT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cast pure titanium (CPT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Zirconia (Zc)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison of MPT and CPT
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 6

Group type: COMPARATOR
Intervention: Surface roughness correlation
Number of subjects: 6
Study: 21641354

Group type: EXPERIMENTAL
Intervention: Transendocardial injection of autologous bone marrow mononuclear cells (ABMMNCs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no ABMMNC treatment)
Number of subjects: 30
Study: 19254211

Group type: EXPERIMENTAL
Intervention: Trimetazidine MR (two weeks prior to CABG and continued for 3 years)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Trimetazidine MR
Number of subjects: 306

Group type: COMPARATOR
Intervention: Conventional therapy of IHD
Number of subjects: 306
Study: 16442924

Group type: EXPERIMENTAL
Intervention: Clopidogrel (loading dose 300 mg followed by 75 mg/d for 8 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Clopidogrel and Placebo
Number of subjects: 73
Study: 15630287

Group type: EXPERIMENTAL
Intervention: Isoflavone supplements (40mg/d)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study: 11332874

Group type: EXPERIMENTAL
Intervention: 1.12 mg chlorphenamine maleate (0.4% nasal spray)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.24 mg chlorphenamine maleate (0.4% nasal spray)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 8 mg chlorphenamine maleate (tablets)
Number of subjects: 24
Study: 9444443

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS) at 50, 100, or 200 micrograms once daily for 7 days
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS) at 50, 100, or 200 micrograms once daily for 14 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS)
Number of subjects: 96
Study: 9037289

Group type: EXPERIMENTAL
Intervention: Bolus injection of vasodilators
Number of subjects: 52

Group type: COMPARATOR
Intervention: Slow injection of vasodilators
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tourniquet use
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bolus injection
Number of subjects: 52

Group type: COMPARATOR
Intervention: Slow injection of low volume drug
Number of subjects: 52
Study: 2667859

Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral xylose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral glucose and xylose
Number of subjects: 14
Study: 822547

Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin daily for 12 weeks followed by once-weekly for 12 months
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 1200 mg rifampicin once-weekly for 12, 18 or 24 months
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 1200 mg rifampicin for longer than 1 year
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 1200 mg rifampicin
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 1200 mg rifampicin for 24 months
Number of subjects: 329
Study: 28252473

Group type: EXPERIMENTAL
Intervention: Moderate-intensity functional exercise program (24 home-based sessions)
Number of subjects: 23
Study: 28934137

Group type: EXPERIMENTAL
Intervention: Hydrolysed soy protein formula
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Free amino acid formula
Number of subjects: 46
Study: 26598474

Group type: EXPERIMENTAL
Intervention: MM+CBT
Number of subjects: 144

Group type: COMPARATOR
Intervention: MM
Number of subjects: 144
Study: 23855681

Group type: EXPERIMENTAL
Intervention: 4 Gy in vitro radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 Gy in vitro radiation
Number of subjects: 0
Study: 21925941

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study: 19380621

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 516

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 516
Study: 16683672

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel with Ca(OH)2
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ca(OH)2
Number of subjects: 3
Study: 15459587

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 60 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 90 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 120 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 150 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous adenosine 140 microg/kg/min
Number of subjects: 50
Study: 11737512

Group type: EXPERIMENTAL
Intervention: Periosonic instruments
Number of subjects: 11

Group type: COMPARATOR
Intervention: Curettes
Number of subjects: 11
Study: 9227247

Group type: EXPERIMENTAL
Intervention: Endorectal ultrasound (EUS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Other techniques (serial CEA levels, digital examination, colonoscopy, pelvic CT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Salvage surgery
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Radiotherapy or other palliative management
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Survival after LR
Number of subjects: 62
Study: 12959311

Group type: EXPERIMENTAL
Intervention: ACE inhibition with fosinopril, 20 mg day(‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2841818

Group type: EXPERIMENTAL
Intervention: estriol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: conjugated estrogens
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: estrogen-gestagen sequential therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: extract from cimicifuga racemosa
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (all therapies)
Number of subjects: 60
Study: 30777123

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 27671460

Group type: EXPERIMENTAL
Intervention: CO2
Number of subjects: 36

Group type: COMPARATOR
Intervention: ICM
Number of subjects: 36
Study: 26108222

Group type: EXPERIMENTAL
Intervention: Oral lysergic acid diethylamide (200 μg)
Number of subjects: 16
Study: 24074332

Group type: EXPERIMENTAL
Intervention: Combination budesonide/formoterol inhaler according to a single inhaler regimen (SMART)
Number of subjects: 303
Study: 20461422

Group type: COMPARATOR
Intervention: Alendronate (5 mg/day)
Number of subjects: 1780

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 μg/day) + Alendronate (5 mg/day)
Number of subjects: 1780
Study: 18300904

Group type: EXPERIMENTAL
Intervention: Single-level, unilateral, lumbar microdiscectomy
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Facet joint angle less than 35 degrees
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Facet joint angle greater than 35 degrees
Number of subjects: 168
Study: 16538542

Group type: EXPERIMENTAL
Intervention: Dose-dense sequential chemotherapy (3 cycles of epirubicin 110 mg/m2 followed by 3 cycles of paclitaxel 250 mg/m2 followed by 3 cycles of intensified CMF)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Standard chemotherapy (4 cycles of epirubicin followed by 4 cycles of CMF)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: HER-2 overexpression
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: High expression of VEGF
Number of subjects: 595
Study: 14499022

Group type: EXPERIMENTAL
Intervention: Spiritual healing treatment (3 weekly sessions lasting approximately 30 minutes each)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal care (no spiritual healing)
Number of subjects: 68
Study: 10920469

Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose, 2.2 +/- 0.7 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Open-label risperidone addition
Number of subjects: 36
Study: 8612028

Group type: EXPERIMENTAL
Intervention: SSZ (2g/day) and pulses of MP (5 mg/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: SSZ (2g/day) and pulses of saline (SA)
Number of subjects: 38
Study: 1420795

Group type: EXPERIMENTAL
Intervention: Structured talk lasting ten minutes and supplied with a 'Guide to Giving up Smoking' (n = 48)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Advised to give up the habit (Control group, n = 50)
Number of subjects: 102
Study: 6692287

Group type: EXPERIMENTAL
Intervention: 30 mg tamoxifen daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30718802

Group type: EXPERIMENTAL
Intervention: Cryotherapy for 2 hours
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cryotherapy for 7 hours
Number of subjects: 94
Study: 29943719

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (5 doses of 2.7 × 10^5 PfSPZ at 0, 4, 8, 12, and 20 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 20
Study: 27338955

Group type: EXPERIMENTAL
Intervention: TRABC in addition to conventional Western treatment
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional Western treatment
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study: 24993276

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with femoral nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spinal anesthesia alone
Number of subjects: 0
Study: 22381530

Group type: EXPERIMENTAL
Intervention: i-SCAN contrast/surface enhancement (CE/SE) mode (i-SCAN1 group; n = 115)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: i-SCAN CE/SE/tone enhancement-colorectal mode (i-SCAN2 group; n = 118)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Conventional high-definition white light (HDWL group; n = 119)
Number of subjects: 389
Study: 20191783

Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Time to eligibility for PACU discharge
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Requirement for airway support
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Incidence of desaturation while in the PACU
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Interval between last dose of relaxant and arrival in PACU
Number of subjects: 102
Study: 18602729

Group type: EXPERIMENTAL
Intervention: Influvac
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Agrippal
Number of subjects: 840
Study: 15894598

Group type: EXPERIMENTAL
Intervention: IFN-gamma1b
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 12025888

Group type: EXPERIMENTAL
Intervention: 10-min infusion of topotecan (1.5 mg/m2/d for 5 days of a 21-day course)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10-min infusion of topotecan
Number of subjects: 12
Study: 12033124

Group type: EXPERIMENTAL
Intervention: Colour cues applied to a free-standing transfer pole for one month in Groups 1 and 2.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with no colour cues applied, views sampled only on exit.
Number of subjects: 30
Study: 7673536

Group type: EXPERIMENTAL
Intervention: Time-limited psychotherapy (TLP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (delayed TLP for 3 months)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Experimental group (TLP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (after waiting)
Number of subjects: 33
Study: 2177970

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMH)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 28
Study: 7077546

Group type: EXPERIMENTAL
Intervention: Exercise (up to 80 W on a bicycle ergometer)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Semi-standardized interview
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Slide viewing (showing parents and marriage partners)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hand ergometer test
Number of subjects: 22

Group type: COMPARATOR
Intervention: All experimental conditions
Number of subjects: 22
Study: 31477187

Group type: EXPERIMENTAL
Intervention: Echocardiographic measurements
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Echocardiographic measurements (limited to 86 patients with similar sedation)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Conventional echocardiographic measures
Number of subjects: 155